Login to Your Account

Preparing For Higher R&D Costs, Cardiome Raises $51M For Trials

By Jennifer Boggs

Monday, March 21, 2005
Expecting an increase in research and development costs this year, Cardiome Pharma Corp. is raising $51 million in a public offering to continue its clinical programs for atrial fibrillation and congestive heart failure. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription